eBook: Beyond Monoclonal Antibodies
Exploring the Next Generation of Antibody Therapeutics
Evolution of monoclonal antibodies (mAbs) has resulted in the next generation of antibody therapeutics, engineered to enhance characteristics such as target cell killing potency. These include antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and nanobodies.
It is important to have robust, high-throughput methods to screen antibody libraries if we are to keep up with the broad and ever-changing disease landscape. To discover effective treatments for rare diseases or against poorly expressed targets, we may need to screen antibody binding, and functional capacity across huge hybridoma or phage display libraries. In addition, if we are to respond rapidly in scenarios such as the COVID-19 pandemic, we need techniques that will identify antibodies with desirable characteristics early in the drug discovery process, in order to quickly send high-quality candidates into the clinical evaluation pipeline.
The iQue® Advanced Flow Cytometry Platform provides an integrated solution, with rapid sampling from 96- and 384-well plates, combined with assay miniaturization. Fast and easy data analysis using iQue Forecyt® software, decreases instrument and data analysis times.
Overview
This eBook explores some of the latest developments in the field of antibody development, highlighting key methodologies used to evaluate novel antibodies across a range of disease areas. A customer interview with one of the leading lights of antibody discovery, Dana Duey, is included.
Document Type: eBook
Page Count: 65
Read Time: 60 minutes
Applications Covered: Flow cytometry
Target Audience: Immunologists, Immuno-oncology, virology researchers, neuroscientists and cancer immunotherapy drug discovery researchers, in biotechnology, pharmaceuticals, biopharma, research institutes and academia.
This eBook includes the following content from experts in the field:
- Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
- Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
- Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
- Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates
- High Throughput, multi-parametric analysis accelerates antibody discovery workflows
- Accelerating antibody therapeutics discovery: Q&A with Dana Duey, AlivaMab Discovery Services
A high throughput technology, to quickly identify candidates with therapeutic potential.
